Encouraging news about the effectiveness of a COVID-19 vaccine candidate comes at a time when infection rates soar
Pfizer announces that its vaccine candidate against COVID-19 effectively prevented infection in 90 percent of previously uninfected people with no serious safety concerns.1
As the first promising vaccine candidate for the virus, the company’s mRNA-based drug BNT162b2 could be a breakthrough in the fight against the coronavirus pandemic.
The company says it plans to submit the drug for Emergency Use Authorization (EUA) to the U.S. Food & Drug Administration (FDA) by the end of November.
Pfizer developed the vaccine alongside German pharmaceutical company BioNTech. Together, they enrolled 43,538 participants in the Phase 3 study, which began on July 27, 2020. As of November 8, 2020, 38,955 participants received a second dose of the vaccine candidate.
The trial will continue to enroll through the final analysis when a total of 164 confirmed COVID-19 cases have accrued, according to a Pfizer statement.1
“The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” says Albert Bourla, DVM, PhD, Pfizer chairman and CEO. “We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”
1. Pfizer. Pfizer and BioNTech accounce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study. Available at: https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-and-BioNTech-Announce-Vaccine-Candidate-Against-COVID-19-Achieved-Success-in-First-Interim-Analysis-from-Phase-3-Study/default.aspx. Accessed 11/9/20.